论文部分内容阅读
选择４０例哮喘病人，实验组（２０例）给予Ｓａｌｍｅｔｅｒｏｌ（施立稳）５０μｇ日２次吸入，对照组（２０例）给予Ｐｒｏｃａｔｅｒｏｌ（美喘清）５０μｇ日２次口服。疗程４周，随访２周。以用药前后ＰＥＦ、ＦＥＶ１、ＦＶＣ变化为观察指标。结果，实验组用药２周肺功能即有改善，清晨ＰＥＦ显著提高（Ｐ＜０．０５）。用药４周时改变最明显（Ｐ＜０．０１）。对照组用药后清晨ＰＥＦ稍有提高，但与用药前相比差别不显著。Ｓａｌｍｅｔｅｒｏｌ可明显提高清晨ＰＥＦ，睡前常规吸入可控制夜间哮喘发作。实验组停药２周肺功能仍保持在基础水平之上，可能与其抗炎作用有关。
Forty asthmatic patients were selected. The experimental group (20 cases) was given Salmeterol (50 μg) twice a day, while the control group (20 cases) was given Procaterol 50 μg twice daily. Treatment for 4 weeks, followed up for 2 weeks. Before and after treatment PEF, FEV1, FVC changes as indicators. Results, the experimental group 2 weeks of lung function improved, early morning PEF was significantly increased (P <0.05). The changes were most obvious after 4 weeks of treatment (P <0.01). In the control group, the PEF slightly increased in the early morning, but the difference was not significant compared with that before treatment. Salmeterol can significantly improve early morning PEF, routine bedtime inhalation can control nighttime asthma attacks. In the experimental group, the lung function remained at the basic level for 2 weeks after stopping the drug, which may be related to its anti-inflammatory effect.